Regeneron Pharmaceuticals Inc. (REGN) UBS Biopharma Conference (Transcript)


Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) UBS Biopharma Conference Call November 9, 2023 11:00 AM ET

Company Participants

Ryan Crowe – Vice President, Investor Relations

Brook Jennings – Vice President, Immunology Marketing

Conference Call Participants

Colin Bristow – UBS

Colin Bristow

Well, good morning, and welcome to the UBS Biopharma Conference. I am Colin Bristow, one of the biotech analysts here. It’s my pleasure to have Regeneron Pharmaceuticals with us today. On behalf of the company, we have Brook Jennings, VP of Commercial Dermatology; and Ryan Crowe, Head of Investor Relations. Thank you both for being with us today. I’ll turn it over to you guys now. I know you have some sort of prepared remarks, and so I’ll leave it to you. Thanks.

Ryan Crowe

Yes, we won’t spend too much time on this, but let me first get the FLS disclosure out of the way. I’d like to remind you that our remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found on Regeneron’s SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements or as a result of new information, future events or otherwise.

With that out of the way, perhaps I’ll just provide a brief recap of the third quarter, and then Brook can talk about DUPIXENT. He’s responsible for the derm indications, but certainly knows the entire brand extremely well. Third quarter is very strong for Regeneron. We had a 15% top line growth, most of which dropped to the bottom line. We had a 4% EPS growth. But when you add back the $100 million IP R&D charge, EPS would have grown 11%. So very strong top and bottom line performance for the



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *